In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfiunction in cardiac myosin binding protein C null mice

摘要

Background: Decreased expression of cardiac myosin binding protein C (cMyBPC) in the heart has been implicated as a consequence of mutations in cMyBPC that lead to abnormal contractile function at the myofilament level, thereby contributing to the development of hypertrophic cardiomyopathy in humans. It has not been established whether increasing the levels of cMyBPC in the intact heart can improve myofilament and in vivo contractile function and attenuate maladaptive remodeling processes because of reduced levels of cMyBPC. Methods and Results: We performed in vivo gene transfer of cMyBPC by direct injection into the myocardium of cMyBPC-deficient (cMyBPC -/-) mice, and mechanical experiments were conducted on skinned myocardium isolated from cMyBPC -/- hearts 21 days and 20 weeks after gene transfer. Cross-bridge kinetics in skinned myocardium isolated from cMyBPC -/- hearts after cMyBPC gene transfer were significantly slower compared with untreated cMyBPC -/- myocardium and were comparable to wild-type myocardium and cMyBPC -/- myocardium that was reconstituted with recombinant cMyBPC in vitro. cMyBPC content in cMyBPC -/- skinned myocardium after in vivo cMyBPC gene transfer or in vitro cMyBPC reconstitution was similar to wild-type levels. In vivo echocardiography studies of cMyBPC -/- hearts after cMyBPC gene transfer revealed improved systolic and diastolic contractile function and reductions in left ventricular wall thickness. Conclusions: This proof-of-concept study demonstrates that gene therapy designed to increase expression of cMyBPC in the cMyBPC-deficient myocardium can improve myofilament and in vivo contractile function, suggesting that cMyBPC gene therapy may be a viable approach for treatment of cardiomyopathies because of mutations in cMyBPC.